Acknowledgements
Cancer
CANCER
The BR36 clinical trial was sponsored by the Cancer Research Institute (funder), the Mark Foundation for Cancer Research (funder) and Personal Genome Diagnostics (vendor for liquid biopsies), and analyses were supported, in part, by Canadian Cancer Society grant 707213 (J.D.), US National Institutes of Health grant CA121113 (V.A.) and the Commonwealth Foundation (V.A.).